Abstract

Described herein are non-binding protein-drug conjugates having increased susceptibility to macropinocytosis by a population of cells in a macropinocytosis-positive disease state relative to a population of cells that are not in a macropinocytosis-positive disease state. The non-binding protein-drug conjugate can comprise a first portion comprising a non- binding protein scaffold that does not substantially bind to a cell surface, wherein the non- binding protein scaffold does not comprise a non-binding fibronectin type III (FN3) domain. A peptide linker can be coupled to and positioned between the first portion and a second portion, wherein the second portion can comprise a pharmaceutically active moiety or a diagnostic moiety.

IPC Classes  ?

• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C08F 112/00 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an aromatic carbocyclic ring
• A61P 35/00 - Antineoplastic agents
• C08F 112/06 - Hydrocarbons